Contineum Therapeutics, Inc. (CTNM) · Nov 3, 2026 · Earnings

Contineum earnings miss as IPF trial expands to 100 sites

Miss — EPS $(0.49) vs ~$0.45 consensus

Contineum’s Q3 earnings missed consensus as spending rose, but the company expanded its lead IPF trial to more than 100 sites.

Contineum is a clinical-stage biotech now concentrated around PIPE-791 and its global Phase 2 PROPEL-IPF trial for idiopathic pulmonary fibrosis; management has been prioritizing that program while keeping cash resources sufficient through mid-2029.

The quarter itself was a modest earnings miss, but not the main business signal. Net loss widened to $18.7 million from $12.8 million, while diluted loss per share was $(0.49) versus a published consensus of roughly $(0.45). Research and development spending rose 45% to $16.0 million as PIPE-791 IPF work accelerated, so the miss reflects heavier investment in the lead program rather than a new revenue problem.

Q3 2026Q3 2025Consensus
Net loss (Financial Statements)$(18.7)M$(12.8)M
Diluted loss per share (Financial Statements)$(0.49)$(0.45)$(0.45)
R&D expense (Financial Statements)$16.0M (+45%)$11.0M
G&A expense (Financial Statements)$5.0M (+26%)$3.9M
Cash and equivalents (Balance Sheet)$75.2M$75.6M at Dec. 31, 2025
Cash plus marketable securities (Balance Sheet)$244.5M$262.9M at Dec. 31, 2025

The operating update is better than the headline EPS result. PROPEL-IPF has expanded from more than 55 sites in eight countries at the prior quarter to more than 100 sites in 16 countries, showing that the global trial is moving into a broader execution phase rather than stalling. The filing does not provide patient-enrollment numbers or a revised completion date, so the site count is evidence of infrastructure progress, not yet proof of faster clinical delivery. 〔0〕

The balance sheet still supports the current plan. Cash, cash equivalents and marketable securities totaled roughly $244.5 million at September 30, down from $262.9 million at year-end, while the company reiterated a cash runway through mid-2029. That leaves the trial funded on the company’s stated plan, although the higher quarterly operating loss shows that the runway depends on continued spending discipline. 〔1〕

Bottom line: The quarter missed modestly on EPS because Contineum is spending more to advance PIPE-791, but the more important development is tangible expansion of the lead IPF trial. This slightly improves the operating story even though the financial scorecard was weaker than expected.

What to watch next

PROPEL-IPF enrollment and Phase 2 trial completion

Original filing on SEC EDGAR

More Contineum Therapeutics, Inc. news

Contineum earnings miss as IPF trial expands to 100 sites | CTNM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.